BioSpace News Archive

Project management software innovator Moovila has been named among CIOReview’s 10 Most Promising Collaboration Solution Providers for 2018.

PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today it will attend and present at the Canaccord Genuity Medical Technologies and Diagnostics Forum

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that preliminary clinical and immunological data from its ongoing KEYNOTE-695 study, a global, multicenter, registration-directed Phase 2b trial of TAVO™ in combination with KEYTRUDA®

The FCS Foundation, the only patient group in the United States focused on supporting patients and families living with familial chylomicronemia syndrome (FCS), today recognizes the first-ever FCS Awareness Day,

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar: “PolarisDMD: Phase 3 Clinical Trial of Edasalonexent, a Novel NF-kB Inhibitor, in Duchenne Muscular Dystrophy,” on Wednesday, November 7, 2018 at 1:00pm ET.

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it will be continuing its ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac

Pono Life Sciences released a white paper, “Rising Above the Opioid Crisis,” that outlines how medical cannabis can help curb America’s opioid crisis.

Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin Green, Cerus’ vice president, finance and chief financial officer, are scheduled to present a corporate update at the 2018 Stephens NY Investment Conference

Arthur J. Gallagher & Co. today announced the acquisition of Auburn, Massachusetts-based John R. Sharry, Inc., dba Group Benefits Strategies. Terms of the transaction were not disclosed.

According to MarketsandMarkets, the global infection control market is expected to reach USD 21.06 Billion by 2022, after having grown from USD 15.35 Billion in 2017. The market is also expected to have a CAGR of 6.5%.